GRAFIX PLUS Placental Membrane

GRAFIX PLUS Placental Membrane is an allogeneic cellular and tissue-based product (CTP) developed for outpatient reality. It offers variability for different wound sizes and takes up limited freezer space. This is human placental tissue engineered to be pulled straight from the shelf and placed directly on the wound.

STRAVIX on blue blob

At a glance

  • Allogenic, lyopreserved placental matrix for wound coverage across head-to-toe locations.
  • Developed for a wide variety of acute and chronic wounds and may be used over exposed bone, tendon, joint capsule, muscle, and hardware.
  • Room-temperature storage with long shelf life to support busy clinic workflows.

Why GRAFIX PLUS is different

GRAFIX PLUS builds on the same placental-tissue science as the broader GRAFIX portfolio: 

  • Placental tissue source with an extracellular matrix that resembles native dermis.1,2
  • Lyopreservation is designed to preserve structural and biochemical integrity while enabling ambient storage.
  • Flexible, conforming cover that drapes over complex anatomies without tearing.

The goal: make high-grade biologic coverage feel routine in the clinic, not exceptional.

woman playing chess
two women potting a plant

Everyday clinical applications

Use GRAFIX PLUS as a wound cover in:

  • Diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs)seen in outpatient settings
  • Post-surgical wounds or dehiscence managed in the clinic
  • Traumatic wounds, graft sites, and other soft-tissue defects requiring biologic support

When paired with standard of care, GRAFIX Membrane products have been associated with improved closure rates and durability of closure in DFUs and VLUs in both trial and real-world settings.3

See the case studies

  1. Dhall S, et al. Plos One. 2018; 13 (10): e0204060.
  2. Mamede AC, Carvalho, MJ, Abrantes AM, et al. Amniotic membrane: from structure and functions to clinical applications. Cell Tissue Res. 2012; 349 (2): 447-458. 
  3. Lavery LA, Fulmer J, Shebetka KA, et al. The efficacy and safety of GRAFIX◊ for the treatment of chronic diabetic foot ulcers: results of a multi-centre, controlled, randomised, blinded, clinical trial. Int Wound J. 2014;11(5):554–560.